Human medicines European public assessment report (EPAR): Pemazyre, pemigatinib, Cholangiocarcinoma, Date of authorisation: 26/03/2021, Status: Authorised

Human medicines European public assessment report (EPAR): Pemazyre, pemigatinib, Cholangiocarcinoma, Date of authorisation: 26/03/2021, Status: Authorised

SEMrush
Human medicines European public assessment report (EPAR): Pemazyre, pemigatinib, Cholangiocarcinoma, Date of authorisation: 26/03/2021, Status: Authorised
[automaticbacklinks]